Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Leukemia

Free Subscription 22.07.2024 2 Am J Hematol 3 Ann Hematol 7 Blood 2 Bone Marrow Transplant 1 Cancer Chemother Pharmacol 1 Cancer Res 1 Eur J Haematol 1 Gene 1 Int J Hematol 1 J Biol Chem 1 Leuk Lymphoma 1 Leuk Res 2 Leukemia 1 PLoS Comput Biol 1 Virology

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. LOGHAVI S, Wei Q, Ravandi F, Quesada AE, et al
   Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia.
   Am J Hematol. 2024 Jul 17. doi: 10.1002/ajh.27435.
   PubMed         Abstract available
   
   
2. MARVIN-PEEK J, Gilbert JS, Pollyea DA, DiNardo CD, et al
   Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?
   Am J Hematol. 2024 Jul 17. doi: 10.1002/ajh.27434.
   PubMed         Abstract available
   
   

   
   Ann Hematol

3. LIPTON JH, Brummendorf TH, Sweet K, Apperley JF, et al
   Practical considerations in the management of patients treated with bosutinib for chronic myeloid leukemia.
   Ann Hematol. 2024 Jul 18. doi: 10.1007/s00277-024-05851.
   PubMed         Abstract available
   
   
4. ZHAO Y, Huang Y, Jiang L, Zhang Y, et al
   Impact of different CEBPA mutations on therapeutic outcome in acute myeloid leukemia.
   Ann Hematol. 2024 Jul 18. doi: 10.1007/s00277-024-05884.
   PubMed         Abstract available
   
   
5. KONTANDREOPOULOU CN, Solomou EE, Kolorizos E, Diamantopoulos PT, et al
   Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia.
   Ann Hematol. 2024 Jul 15. doi: 10.1007/s00277-024-05869.
   PubMed         Abstract available
   
   

   
   Blood

6. TE VRUGT M, Wessolowski JS, Randau G, Alfert A, et al
   Pediatric T-cell lymphoblastic lymphoma but not leukemia harbor TRB::NOTCH1 fusions with unfavorable outcome.
   Blood. 2024 Jul 18:blood.2024025307. doi: 10.1182/blood.2024025307.
   PubMed         Abstract available
   
   
7. 
   van der Straten L, Stege CAM, Kersting S, et al. Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL. Blood. 2023;142(13):1131-1142.
   Blood. 2024;144:341.
   PubMed        
   
   
8. 
   Melnick AF, Mullin C, Lin K, et al. Cdc73 protects Notch-induced T-cell leukemia cells from DNA damage and mitochondrial stress. Blood. 2023;142(25):2159-2174.
   Blood. 2024;144:342.
   PubMed        
   
   
9. RADICH J
   Transplant, MRD, and predicting relapse in AML.
   Blood. 2024;144:245-247.
   PubMed        
   
   
10. OPAT S
    Treatment of relapsed CLL "in the BAAG"?
    Blood. 2024;144:243-244.
    PubMed        
    
    
11. MUFFLY L, Liang EC, Dolan JG, Pulsipher MA, et al
    How I use next-generation sequencing-MRD to plan approach and prevent relapse after HCT for children and adults with ALL.
    Blood. 2024;144:253-261.
    PubMed         Abstract available
    
    
12. FURSTENAU M, Giza A, Weiss J, Kleinert F, et al
    Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial.
    Blood. 2024;144:272-282.
    PubMed         Abstract available
    
    

    
    Bone Marrow Transplant

13. AHN J, Yoon JH, Kwag D, Min GJ, et al
    Comparative analysis of reduced toxicity conditioning regimens between fludarabine plus melphalan and fludarabine plus busulfex in adult patients with acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2024 Jul 12. doi: 10.1038/s41409-024-02363.
    PubMed         Abstract available
    
    
14. GANZEL C, Wang Y, Roopcharan K, Sun Z, et al
    Correction: Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRIN trials.
    Bone Marrow Transplant. 2024 Jul 18. doi: 10.1038/s41409-024-02337.
    PubMed        
    
    

    
    Cancer Chemother Pharmacol

15. RAHMAYANTI SU, Amalia R, Rusdiana T
    Systematic review: genetic polymorphisms in the pharmacokinetics of high-dose methotrexate in pediatric acute lymphoblastic leukemia patients.
    Cancer Chemother Pharmacol. 2024 Jul 13. doi: 10.1007/s00280-024-04694.
    PubMed         Abstract available
    
    

    
    Cancer Res

16. SCHNEIDER C, Spaink H, Alexe G, Dharia NV, et al
    Targeting the Sodium-Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia.
    Cancer Res. 2024 Jul 18. doi: 10.1158/0008-5472.CAN-23-3560.
    PubMed         Abstract available
    
    

    
    Eur J Haematol

17. ACKER F, Chromik J, Tiedjen E, Wolf S, et al
    Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy.
    Eur J Haematol. 2024 Jul 18. doi: 10.1111/ejh.14278.
    PubMed         Abstract available
    
    

    
    Gene

18. NIIBORI-NAMBU A, Wang CQ, Chin DWL, Chooi JY, et al
    Integrin-alpha9 overexpression underlies the niche-independent maintenance of leukemia stem cells in acute myeloid leukemia.
    Gene. 2024;928:148761.
    PubMed         Abstract available
    
    

    
    Int J Hematol

19. IKEDA S, Suzuki M, Tsunoda S, Ohta M, et al
    Dynamic changes in femoral bone marrow MRI in patients with chronic myelogenous leukemia.
    Int J Hematol. 2024 Jul 15. doi: 10.1007/s12185-024-03819.
    PubMed        
    
    

    
    J Biol Chem

20. RAMANI M, Singh RK, Shrivastva S, Ribeyron L, et al
    A pre-B acute lymphoblastic leukemia cell line model reveals the mechanism of thalidomide therapy related B-cell leukemogenesis.
    J Biol Chem. 2024 Jul 17:107578. doi: 10.1016/j.jbc.2024.107578.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

21. TRAN QUANG V, Wagner-Ballon O, Sloma I
    Predicting which subsets of patients with myelodysplastic neoplasms are more likely to progress to overt chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2024 Jul 14:1-11. doi: 10.1080/10428194.2024.2378816.
    PubMed         Abstract available
    
    

    
    Leuk Res

22. KONG C, Wu M, Lu Q, Ke B, et al
    PI3K/AKT confers intrinsic and acquired resistance to pirtobrutinib in chronic lymphocytic leukemia.
    Leuk Res. 2024;144:107548.
    PubMed         Abstract available
    
    

    
    Leukemia

23. KONOPLEVA M, Milella M, Ruvolo P, Watts JC, et al
    Retraction Note: MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
    Leukemia. 2024 Jul 18. doi: 10.1038/s41375-024-02339.
    PubMed        
    
    
24. ORVAIN C, Bertoli S, Peterlin P, Desbrosses Y, et al
    Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study.
    Leukemia. 2024 Jul 17. doi: 10.1038/s41375-024-02335.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

25. SCHMIDT-BARBO P, Kalweit G, Naouar M, Paschold L, et al
    Detection of disease-specific signatures in B cell repertoires of lymphomas using machine learning.
    PLoS Comput Biol. 2024;20:e1011570.
    PubMed         Abstract available
    
    

    
    Virology

26. YANG A, Wang X, Jin L, Luo H, et al
    Human umbilical cord mesenchymal stem cell exosomes deliver potent oncolytic reovirus to acute myeloid leukemia cells.
    Virology. 2024;598:110171.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.